<DOC>
	<DOCNO>NCT00081159</DOCNO>
	<brief_summary>RATIONALE : Androgens stimulate growth prostate cancer cell . Drugs goserelin leuprolide may fight prostate cancer stop adrenal gland produce androgen . Drugs use chemotherapy doxorubicin work different way stop tumor cell divide stop grow die . Zoledronate may prevent bone loss stop growth tumor cell bone . Radioactive substance strontium-89 may relieve bone pain associated prostate cancer . It yet know whether hormone ( androgen ) ablation therapy chemotherapy combine zoledronate effective without strontium-89 treat prostate cancer bone metastasis . PURPOSE : This randomized phase II trial study give hormone ablation therapy , doxorubicin , zoledronate together strontium-89 see well work compare hormone ablation therapy , doxorubicin , zoledronate alone treat patient androgen-dependent prostate cancer bone metastasis .</brief_summary>
	<brief_title>Hormone Ablation Therapy , Doxorubicin , Zoledronate With Without Strontium 89 Treating Patients With Androgen-Dependent Prostate Cancer Bone Metastases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare clinical efficacy hormonal ablative therapy combine doxorubicin zoledronate without strontium chloride Sr 89 , term progression-free survival , patient androgen-dependent prostate cancer bone metastasis . OUTLINE : This randomize , multicenter study . Patients stratify accord number bony metastasis ( â‰¤ 6 versus &gt; 6 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive hormonal ablative therapy comprise luteinizing hormone-releasing hormone agonist ( e.g. , leuprolide goserelin ) continuously study treatment OR bilateral orchiectomy . Patients also receive doxorubicin intravenously ( IV ) day 1 , 8 , 15 every 28 day 2 course ; zoledronate IV 15 minute day 1 every 28 day 6 course ; single dose strontium chloride Sr 89 IV 1-2 minute day 1 . - Arm II : Patients receive hormonal ablative therapy , doxorubicin , zoledronate arm I . In arm , treatment continue absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 80 patient ( 40 per treatment arm ) accrue study within 20 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>1 . Histologically cytologically confirm prostate carcinoma . 2 . Osteoblastic metastasis bone scan compute tomography ( CT ) scan . 3 . Initiation hormonal ablative therapy within 3 month registration . 4 . Prior neoadjuvant , concurrent , intermittent hormonal ablative therapy le 3 year duration complete least 3 year prior entry study . 5 . The Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 3 ( Karnofsky &gt; 40 % ) 6 . Patients must normal organ marrow function define : leukocyte : &gt; 3,000/mL ; absolute neutrophil count : &gt; 1,500/mL ; platelet : &gt; 100,000/mL ; total bilirubin within normal institutional limit ; alanine transaminase ( ALT ) ( SGPT ) /aspartate aminotransferase ( AST ) ( SGOT ) : &lt; 2.5 * institutional upper limit normal ; creatinine : &lt; = 3.0 ; leave ventricular ejection fraction : &gt; 45 % 7 . The effect strontium89 zoledronic acid develop human fetus recommend therapeutic dose unknown . Even though patient castrate study , men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should spouse patient become pregnant suspect pregnant participating study , she/he inform treat physician immediately . 8 . Ability understand willingness sign write informed consent document . 1 . More one prior chemotherapy regimen . Prior doxorubicin treatment permit . However patient 's &gt; 250 mg/m2 cumulative dosage exclude . 2 . Prior radioisotope treatment consist strontium89 samarium153 . 3 . Zoledronic acid treatment 3 month duration prior registration . Other bisphosphonate treatment permit . 4 . Corrected serum calcium level le 8 mg/dL . 5 . Patients may receive investigational agent . 6 . Patients know brain metastasis exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . 7 . History allergic reaction attribute compound similar chemical biologic composition zoledronic acid agent use study 8 . Patients follow atypical presentation biopsy : small cell carcinoma , purely lytic bone metastasis , bulky ( i.e . 5 cm ) visceral nodal disease absence bone involvement eligible . 9 . Symptomatic bulky lymphadenopathy cause scrotal pedal edema significant local invasive disease bladder invasion . 10 . History malignancy nonmelanoma skin cancer , unless complete remission therapy disease least 5 year . 11 . Uncontrolled intercurrent illness include , limited , ongoing active infection , history congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 12 . Because patient immune deficiency increase risk lethal infection treat marrowsuppressive therapy , HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction strontium89 agent administer study . Appropriate study undertake patient receive combination antiretroviral therapy indicate . 13 . Evidence suspicion myelodysplastic syndrome complete blood test ( CBC ) must confirm bone marrow biopsy . 14 . Untreated symptomatic spinal cord compression .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>bone metastasis</keyword>
</DOC>